The first participant to take part in the RADAR-AD study was included on 10 July in the project’s clinical site in Thessaloniki, Greece. This marked the official start of the RADAR-AD clinical study, despite a short delay due to the COVID-19 pandemic.
In the upcoming weeks the RADAR-AD consortium expects more inclusions to follow at its other clinical sites.
Read the full story, here.
